Bibliotecas PUC-SP - Busca Integrada

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma

著者: Andrey Moiseyenko, Franco Muggia, Thomas Condamine, Jennifer Pulini, John E. Janik, Daniel C. Cho
出版年 Gynecologic Oncology Reports (2020-11-01)

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

著者: Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu
出版年 Journal for ImmunoTherapy of Cancer (2021-07-01)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

著者: Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz
出版年 Journal for ImmunoTherapy of Cancer (2022-04-01)

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

著者: Rebecca Kristeleit, Juan Martin-Liberal, Kristen Spencer, Janice M Mehnert, Maria Vieito, Elizabeth J Davis, Angela Orcurto, Thomas Condamine, Daniel C Cho, Jennifer Pulini, Rowan E Miller, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Prashanth Hari Dass, John E Janik, Jason Clark, Xuejun Chen
出版年 Journal for ImmunoTherapy of Cancer (2022-10-01)

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

著者: Mario Sznol, Michael Yellin, Tibor Keler, Jose Lutzky, Amy Weise, Margaret K Callahan, Osama Rahma, Rachel E Sanborn, Alexander Starodub, Deepa S Subramaniam, Antonio Jimeno, Tracey Rawls, David A Reardon, Daniel C Cho, Rhonda L Bitting, Michael J Pishvaian, Branimir I Sikic, Naiyer A Rizvi, Julie E Bauman, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Jeanny B Aragon-Ching, Thomas R Hawthorne
出版年 Journal for ImmunoTherapy of Cancer (2022-08-01)

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

著者: Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
出版年 Journal for ImmunoTherapy of Cancer (2023-03-01)